Stirred and Shaken: Strengthening supply chains and navigating trade war chaos
Speakers
The U.S. administration’s constantly-evolving tariffs policy is having an impact on a broad spectrum of industries, hiking prices on many imported goods and creating uncertainty for investors. For pharmas, however, threatened tariffs on imported drugs and components is the shoe yet to drop. The President has vowed various tariff rates on prescription drugs – of 200%, of 250%. Even a more modest tariff could have a substantial impact on drug manufacturers, payers and patients. Upscaling domestic production to compensate could take companies many years, and could result in drug supply snarls in the meantime.
In this on-demand webinar, we discuss the potential impacts of a U.S. tariff regime on imports of pharmaceuticals, biologics and precursor chemicals, as well as how the administration’s tariffs policy, whether promised or already in place, is already impacting the pharmaceutical industry and cover:
- How drug companies can manage uncertainty around imports and tariffs
- What categories and modalities are particularly vulnerable to disruption by tariffs
- Costs and other challenges of building domestic U.S. manufacturing capacity
- API sourcing and supply chain implications for U.S. patients and providers
